Attralus

Clinical Stage Biotech Company focused on improving the lives of systemic amyloidosis patients

[Attralus @attralus]

@Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus. Read the press release: https://t.co/s2LNk5koUE. #amyloidosis

[Attralus @attralus]

Attralus announced FDA orphan drug designation for zamubafusp alfa (AT-02) in AL amyloidosis, a rare, progressive disease.
Read more 👉 https://t.co/6revmryYCI
#Amyloidosis #ALAmyloidosis #RareDisease #OrphanDrug #FDA

[Attralus @attralus]

Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at #ASH2025. Read the press release: https://t.co/GarWmp0nCf #amyloidosis

[Attralus @attralus]

Attralus presents new Data on its pan-amyloid diagnostic imaging candidates at #ASNC2025. Read the press release: https://t.co/zmE4gfj6KB #amyloidosis

[Attralus @attralus]

Attralus presents new data on our pan-amyloid diagnostic candidates at #ACC2025. Read the press release: https://t.co/EDxXBkP3uy #amyloidosis

[Attralus @attralus]

Attralus announces enrollment of first patient in Phase 3 trial for the pan-amyloid diagnostic 124I-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release: https://t.co/MbcLPAeA2T.

[Attralus @attralus]

Attralus receives Orphan Drug Designation from @US_FDA for AT-02 for the treatment of ATTR #amyloidosis. Read the press release: https://t.co/VsgX7vRZuX

[Attralus @attralus]

Attralus is excited to announce that we have received Breakthrough Therapy Designation for our pan-amyloid diagnostic PET imaging candidate I124-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release: https://t.co/v8FYW4hFOS.

[Attralus @attralus]

Attralus receives EMA Committee for Orphan Medicinal Products positive opinions for AT-02 for treatment of both ATTR and AL #amyloidosis. Read the press release: https://t.co/jb5H8adLjj

[Attralus @attralus]

Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at #ISA2024. Read the press release at https://t.co/WDg5D9or2f. #amyloidosis

[Attralus @attralus]

Looking forward to @ISA_Amyloidosis #ISA_2024 in Rochester, MN on 26-30 May. We are proud to announce 16 presentations, incl 3 oral presentations, highlighting our investigational agents and continued commitment to #amyloidosis patients. Learn more: https://t.co/o2GJdv67m8.

[Attralus @attralus]

On #raredisease day we honor rare disease patients waiting for new treatments, the patient advocacy groups and healthcare providers working tirelessly to improve patients' lives, and especially the many #amyloidosis patients as they battle with this rare and devastating disease.

[Attralus @attralus]

We are excited to announce the closing of our $56 million financing. Read more: https://t.co/jRQCpSfH9n #amyloidosis

[Attralus @attralus]

Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging) #JACCIMG Read more - https://t.co/otAuTkSbxq #amyloidosis

[Attralus @attralus]

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at #ASNC2023
Read more - https://t.co/GiNoglS8P9 #amyloidosis

[Attralus @attralus]

For #NationalAmyloidosisDay, a reminder that #amyloidosis is a #raredisease that is progressive and debilitating, and as many as 80% of patients worldwide go undiagnosed or wait years to receive a diagnosis. Learn more about systemic #amyloidosis @ https://t.co/tdnmgzvf7B.

[Alzforum @alzforum]

New ways to target pathologic tau focus on intracellular tau, vaccines, and multivalent molecules that attack several types of fibril. #alzheimersdisease https://t.co/0x3SNjXiWw

[Parkinson's News Today @parkinsonstory]

Attralus' experimental therapies, AT-04 and AT-07, are able to bind to proteins causing toxic clumps in Parkinson's, suggesting new treatment possibilities. https://t.co/2N2cMdLM8x

#parkinsonsdiseaseresearch #parkinsonsdisease #livingwithparkinsons

[Amyloidosis Speakers Bureau @Amyloidosis_ASB]

Informative video from Dr. Jonathan Wall of @attralus describing their work to develop non-invasive imaging to diagnose amyloid deposits. Great stuff.
#amyloidosis
https://t.co/1rPPdsNu1a

[Attralus @attralus]

New preclinical data on AT-04 and AT-07, our pan-amyloid removal therapeutics targeting neurodegenerative disorders was presented this past weekend at #ADPD2023. Read more https://t.co/VnbX3ths7F #amyloidosis #AlzheimersDisease